Hepa Wash GmbH
ADVITOS GmbH is a Munich-based medical technology company dedicated to developing innovative therapies for multiorgan support. Their flagship product, the ADVOS therapy, is a CE-certified and globally patented system that supports the liver, lung, and kidney simultaneously, improving survival rates for critically ill patients. The company aims to establish effective organ support and acidosis therapies as standard care worldwide, with a focus on advancing their next-generation blood purification system, the ADVOS BK300. They are committed to research, development, and clinical validation to enhance patient outcomes and expand their international presence.
Industries
Nr. of Employees
medium (51-250)
Hepa Wash GmbH
Agnes-Pockels-Bogen 1, 80992 München
Patents
Products
Multiorgan extracorporeal support system (integrated device platform)
A multifunction extracorporeal therapy platform engineered to support kidney, liver and lung detoxification while enabling direct blood pH correction and integrated renal replacement therapy; designed for continuous ICU use and modular therapy configuration.
Multiorgan extracorporeal support system (integrated device platform)
A multifunction extracorporeal therapy platform engineered to support kidney, liver and lung detoxification while enabling direct blood pH correction and integrated renal replacement therapy; designed for continuous ICU use and modular therapy configuration.
Services
Design, coordination and execution support for clinical studies and registries to establish medical evidence for extracorporeal multiorgan therapies.
Hands-on and theoretical training workshops for clinicians and nursing staff covering device setup, therapy management and troubleshooting.
On-site installation, maintenance and rapid-response technical service for therapy systems and associated consumables.
Manufacture and provision of treatment fluids/concentrates and single-use consumables required for extracorporeal treatments.
Design, coordination and execution support for clinical studies and registries to establish medical evidence for extracorporeal multiorgan therapies.
Hands-on and theoretical training workshops for clinicians and nursing staff covering device setup, therapy management and troubleshooting.
On-site installation, maintenance and rapid-response technical service for therapy systems and associated consumables.
Manufacture and provision of treatment fluids/concentrates and single-use consumables required for extracorporeal treatments.
Expertise Areas
- Multiorgan extracorporeal support therapies
- Clinical trial planning and evidence generation
- Medical device development and human factors engineering
- Regulatory compliance for medical devices (ISO 13485, MDR, CE)
Key Technologies
- Extracorporeal blood purification
- Albumin-based dialysis
- Renal replacement therapy (RRT) integration
- Extracorporeal CO2 removal
News & Updates
The company received the Red Dot Product Design Award and the Red Dot Innovative Design Award for their ADVOS BK300 system, recognizing excellence in design and innovation.
The company has finalized its financial restructuring through a court-approved insolvency plan, securing long-term support and preparing for the launch of the next generation of their multiorgan support system.
Advitos announced the closing of a €20 million funding round led by Crédit Mutuel Equity and the European Innovation Council Fund, aimed at advancing their multiorgan support systems and clinical validation.
The Munich-based medtech company was recognized for its innovative ADVOS therapy, which supports multiple organs and has the potential to save lives in intensive care.
Ranked 27th among Deloitte Technology Fast 50 with a growth rate of 680%.
Received a Seal of Excellence for top-tier innovations and a €2.3 million EIC Accelerator grant.
The company received the Red Dot Product Design Award and the Red Dot Innovative Design Award for their ADVOS BK300 system, recognizing excellence in design and innovation.
The company has finalized its financial restructuring through a court-approved insolvency plan, securing long-term support and preparing for the launch of the next generation of their multiorgan support system.
Advitos announced the closing of a €20 million funding round led by Crédit Mutuel Equity and the European Innovation Council Fund, aimed at advancing their multiorgan support systems and clinical validation.
The Munich-based medtech company was recognized for its innovative ADVOS therapy, which supports multiple organs and has the potential to save lives in intensive care.
Ranked 27th among Deloitte Technology Fast 50 with a growth rate of 680%.
Received a Seal of Excellence for top-tier innovations and a €2.3 million EIC Accelerator grant.